Abstract 4791: Metabolic switch from glycolysis to oxidative phosphorylation (ox-phos) provides survival advantage to anti-androgen-treated prostate cancer cells and make them vulnerable to mitochondrial metabolism inhibitors IACS-010759 and CB-839

MLA

G. Wilding, et al. “Abstract 4791: Metabolic Switch from Glycolysis to Oxidative Phosphorylation (Ox-Phos) Provides Survival Advantage to Anti-Androgen-Treated Prostate Cancer Cells and Make Them Vulnerable to Mitochondrial Metabolism Inhibitors IACS-010759 and CB-839.” Cancer Research, vol. 80, Aug. 2020, p. 4791. EBSCOhost, https://doi.org/10.1158/1538-7445.am2020-4791.

APA

G. Wilding, Nathaniel Wilganowski, Evan N. Cohen, Mark Titus, James M. Reuben, Sumankalai Ramachandran, Samantha Robertson, Hirak S. Basu, & Amado Zurita-Saavedra. (2020). Abstract 4791: Metabolic switch from glycolysis to oxidative phosphorylation (ox-phos) provides survival advantage to anti-androgen-treated prostate cancer cells and make them vulnerable to mitochondrial metabolism inhibitors IACS-010759 and CB-839. Cancer Research, 80, 4791. https://doi.org/10.1158/1538-7445.am2020-4791

Chicago

G. Wilding, Nathaniel Wilganowski, Evan N. Cohen, Mark Titus, James M. Reuben, Sumankalai Ramachandran, Samantha Robertson, Hirak S. Basu, and Amado Zurita-Saavedra. 2020. “Abstract 4791: Metabolic Switch from Glycolysis to Oxidative Phosphorylation (Ox-Phos) Provides Survival Advantage to Anti-Androgen-Treated Prostate Cancer Cells and Make Them Vulnerable to Mitochondrial Metabolism Inhibitors IACS-010759 and CB-839.” Cancer Research 80 (August): 4791. doi:10.1158/1538-7445.am2020-4791.